Taconic Capital Advisors’s Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share DNA.WS Stock Holding History

Taconic Capital Advisors’s Portfolio DNA.WS Stock Details DNA.WS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-88,000	Closed	-$23.1K	–	213
2023 Q2	$23.1K	Hold	88,000	–	–	﹤0.01%	147
2023 Q1	$15.8K	Hold	88,000	–	–	﹤0.01%	226
2022 Q4	$17.6K	Hold	88,000	–	–	﹤0.01%	389
2022 Q3	$63K	Sell	88,000 -76,760	-47%	-$52.5K	﹤0.01%	430
2022 Q2	$87K	Buy	+164,760	New	+$104K	﹤0.01%	444
2022 Q1	–	Sell	-186,072	Closed	-$417K	–	716
2021 Q4	$417K	Hold	186,072	–	–	0.01%	340
2021 Q3	$631K	Buy	+186,072	New	+$663K	0.02%	269

Other funds holding DNA.WS

LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return

Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Altshuler Shaham Tel Aviv, Israel $5.54B AUM 44.68% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

ICM

Ionic Capital Management New York $1.37B AUM 48.26% 1-Year Est. Return

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

JRCM

Jones Road Capital Management New York $55.3M AUM 29.97% 1-Year Est. Return

Guggenheim Capital Chicago, Illinois $12.9B AUM 27.3% 1-Year Est. Return

Walleye Trading New York $60B AUM 42.19% 1-Year Est. Return

Taconic Capital Advisors's DNA.WS Position: Q3 2023 in Review

Taconic Capital Advisors sold out of Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share (DNA.WS) in Q3 2023, closing a stake of 88,000 shares — an estimated $23.1K sold.

Taconic Capital Advisors first reported a position in DNA.WS in Q3 2021 and held it in 7 quarters. The position peaked at $631K in Q3 2021. 33 funds tracked by Wall St. Rank hold DNA.WS as of Q3 2023.

Taconic Capital Advisors reported no remaining Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share position as of Q3 2023 after selling out during the quarter.
Taconic Capital Advisors sold 88,000 Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share shares in Q3 2023, an estimated $23.1K.
Taconic Capital Advisors first reported a position in Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share in Q3 2021 and held it in 7 quarters.
Taconic Capital Advisors's Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share position peaked at $631K in Q3 2021.
33 funds tracked by Wall St. Rank held Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share as of Q3 2023.

Based on Taconic Capital Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.